Skip to main content
. 2017 Mar 21;52(10):1101–1111. doi: 10.1007/s00535-017-1326-1

Fig. 1.

Fig. 1

Study design and patient disposition. E Primary efficacy evaluation, DB double-blind, I-week induction week, M-week maintenance week, OL open-label, SC subcutaneous; a every 4 weeks through M-week 52; b patients who responded to golimumab 100 mg at M-week 8 continued to receive golimumab 100 mg every 4 weeks through M-Week 52 at the same dose